Table 3

Histone deacetylase inhibitors approved or in ongoing clinical trials in cutaneous T-cell lymphomas

Agent	Specificity	Structural class	Route	Clinical status in CTCL	References
Vorinostat	Pan	Hydroxamic acid	Oral	FDA-approved	¹⁴⁰
Romidepsin	HDAC1/2	Bicyclic peptide	IV	FDA-approved	²¹
Belinostat	Pan	Hydroxamic acid	IV	FDA-approved	¹⁴²
Chidamide	HDAC1/2/3/10	Benzamides	Oral	NMPA-approved	¹⁴⁴
Panobinostat	Pan	Hydroxamic acid	Oral	Phase II trial—R/R CTCL	¹⁴⁵
SHP-141	Unknown	Hydroxamic acid	Topical	Phase II trial—stage IA-IB CTCL	¹⁴⁷

CTCL, cutaneous T-cell lymphoma; FDA, Food and Drug Administration; HDAC, histone deacetylase; IV, intravenous; NMPA, National Medical Products Administration (China); R/R, refractory/recurrent.